Rallybio Corporation Announces Initiation of Additional Preclinical Studies for REV102, Secures $12.5 Million Milestone Payment from Recursion

Reuters

09/03

Rallybio Corporation Announces Initiation of Additional Preclinical Studies for REV102, Secures $12.5 Million Milestone Payment from <a href="https://laohu8.com/S/RXRX">Recursion</a>

Rallybio Corporation, a clinical-stage biotechnology company, has announced the receipt of a $12.5 million equity milestone payment from Recursion. This payment was triggered by the initiation of additional preclinical studies for REV102, a potential first-in-class oral ENPP1 inhibitor aimed at treating hypophosphatasia $(HPP)$. The milestone payment extends Rallybio's cash runway through 2027. The company is looking forward to sharing topline data from the confirmatory PK/PD study of RLYB116 in the coming months. Results for the REV102 program have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250902608819) on September 03, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2564398087"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564398087\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564398087?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-03 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564398087","market":"nz","top_or_hot":-1,"title":"Rallybio Corporation Announces Initiation of Additional Preclinical Studies for REV102, Secures $12.5 Million Milestone Payment from Recursion","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Rallybio Corporation Announces Initiation of Additional Preclinical Studies for REV102, Secures $12.5 Million Milestone Payment from <a href=\"https://laohu8.com/S/RXRX\">Recursion</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Rallybio Corporation, a clinical-stage biotechnology company, has announced the receipt of a $12.5 million equity milestone payment from Recursion. This payment was triggered by the initiation of additional preclinical studies for REV102, a potential first-in-class oral ENPP1 inhibitor aimed at treating hypophosphatasia <a href=\"https://laohu8.com/S/HPP\">$(HPP)$</a>. The milestone payment extends Rallybio's cash runway through 2027. The company is looking forward to sharing topline data from the confirmatory PK/PD study of RLYB116 in the coming months. Results for the REV102 program have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250902608819) on September 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rallybio Corporation Announces Initiation of Additional Preclinical Studies for REV102, Secures $12.5 Million Milestone Payment from Recursion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRallybio Corporation Announces Initiation of Additional Preclinical Studies for REV102, Secures $12.5 Million Milestone Payment from Recursion\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-03 20:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Rallybio Corporation Announces Initiation of Additional Preclinical Studies for REV102, Secures $12.5 Million Milestone Payment from <a href=\"https://laohu8.com/S/RXRX\">Recursion</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Rallybio Corporation, a clinical-stage biotechnology company, has announced the receipt of a $12.5 million equity milestone payment from Recursion. This payment was triggered by the initiation of additional preclinical studies for REV102, a potential first-in-class oral ENPP1 inhibitor aimed at treating hypophosphatasia <a href=\"https://laohu8.com/S/HPP\">$(HPP)$</a>. The milestone payment extends Rallybio's cash runway through 2027. The company is looking forward to sharing topline data from the confirmatory PK/PD study of RLYB116 in the coming months. Results for the REV102 program have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250902608819) on September 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL767vCx:1","article_id":"2564398087","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564398087","pubTimestamp":1756900871,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Rallybio Corporation Announces Initiation of Additional Preclinical Studies for REV102, Secures $12.5 Million Milestone Payment from Recursion. Rallybio Corporation, a clinical-stage biotechnology company, has announced the receipt of a $12.5 million equity milestone payment from Recursion. This payment was triggered by the initiation of additional preclinical studies for REV102, a potential first-in-class oral ENPP1 inhibitor aimed at treating hypophosphatasia . The milestone payment extends Rallybio's cash runway through 2027. The company is looking forward to sharing topline data from the confirmatory PK/PD study of RLYB116 in the coming months. Results for the REV102 program have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","RLYB":"Rallybio Corp."},"translate_title":"Rallybio Corporation宣布启动REV102的额外临床前研究，并从Recursion获得1250万美元的里程碑付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLYB":0.9},"content_text":"Rallybio Corporation Announces Initiation of Additional Preclinical Studies for REV102, Secures $12.5 Million Milestone Payment from Recursion\n\n\n        Rallybio Corporation, a clinical-stage biotechnology company, has announced the receipt of a $12.5 million equity milestone payment from Recursion. This payment was triggered by the initiation of additional preclinical studies for REV102, a potential first-in-class oral ENPP1 inhibitor aimed at treating hypophosphatasia $(HPP)$. The milestone payment extends Rallybio's cash runway through 2027. The company is looking forward to sharing topline data from the confirmatory PK/PD study of RLYB116 in the coming months. Results for the REV102 program have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250902608819) on September 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}